Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

CRP is Not a Better Marker for CVD than LDL

Introduction to LDL and CRP

  • The American Heart Association and American College of Cardiology explicitly state that LDL cholesterol remains the primary target for cardiovascular disease risk assessment and treatment, while CRP serves only as an adjunctive risk marker in select intermediate-risk patients 1, 2, 3

Why LDL Takes Priority Over CRP

  • LDL cholesterol directly causes atherosclerosis, with extensive randomized controlled trial evidence demonstrating that lowering LDL-C reduces cardiovascular events and mortality 4
  • The American College of Cardiology recommends that risk assessment should not place emphasis on comparison to a single variable such as LDL-C, meaning CRP must be evaluated within comprehensive risk models, not as a standalone superior marker 2, 3

LDL Has Proven Treatment Targets, CRP Does Not

  • Randomized trials consistently demonstrate that LDL-lowering therapies reduce cardiovascular events, with clear dose-response relationships between LDL-C reduction and clinical benefit 4
  • Guidelines explicitly state that serial testing of hsCRP should not be used to monitor treatment effects, whereas LDL-C is the primary treatment target 6

The Limited Role of CRP in Clinical Practice

  • The American Heart Association recommends that hsCRP can be measured in intermediate-risk patients to help reclassify them to higher risk categories and justify more aggressive LDL-lowering targets 1, 6
  • hsCRP may be used at physician discretion as part of global risk assessment in primary prevention, but the benefits of this strategy remain uncertain 6

Critical Limitations of CRP

  • CRP does not reliably predict the extent of angiographically defined atherosclerosis 2, 3
  • Application of secondary prevention measures should not depend on hsCRP determination 6
  • Management of acute coronary syndromes should not be guided by hsCRP levels 6

Superior Alternatives to Both LDL and CRP

  • Non-HDL cholesterol and apolipoprotein B are superior to LDL-C for predicting CHD events in multiple meta-analyses and can be measured in non-fasting samples 7
  • These markers capture the total burden of atherogenic particles better than LDL-C alone 7

Common Pitfalls to Avoid

  • The American College of Cardiology recommends that CRP should not be used to guide lipid-lowering therapy intensity—use LDL-C, non-HDL-C, or apoB as primary targets 6
  • Persistently elevated CRP >10 mg/L should prompt evaluation for non-cardiovascular causes such as infection or systemic inflammation 1, 6